H.C. Wainwright analyst Oren Livnat downgraded Zynerba Pharmaceuticals (ZYNE) to Neutral from Buy without a price target after the company agreed to be acquired by Harmony Biosciences (HRMY). The firm does not expect a higher bidder, and notes the deal is projected to close in Q4.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ZYNE:
- Zynerba downgraded to Neutral from Buy at Ladenburg
- Zynerba Pharma (NASDAQ:ZYNE) Skyrockets 3x on Acquisition by Harmony Bio (NASDAQ:HRMY)
- Harmony Biosciences to acquire Zynerba
- HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
- Rising High: Exclusive talk with cannabis market research firm BDSA
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue